Clinical studies of Seladelpar – new analysis
New analyses of clinical studies of Seladelpar were presented during Digestive Disease Week® (DDW) in San Diego on May 23, 2022. The three presentations were:
“Seladelpar Treatment of Patients With Primary Biliary Cholangitis (PBC) For 2 Years Improves the GLOBE PBC Score and Predicts Improved Transplant-Free Survival” by Dr. Bettina Hansen, PhD, Associate Professor of Biostatistics at the University of Toronto, Toronto, CA and Erasmus University Medical Center, Rotterdam, NL.
“Efficacy, Safety, and Tolerability of Seladelpar in Patients With Compensated Liver Cirrhosis Due to Primary Biliary Cholangitis (PBC): A Pooled Analysis of Phase 2 and Phase 3 Studies” was delivered by Dr. Stuart Gordon, MD, Professor of Medicine at Wayne State University and Director of the Division of Hepatology and GI Research at Henry Ford Health System.
“Treatment With Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and Prior Experience With Obeticholic Acid (OCA) or Fibrates” authored by Dr. Aliya Gulamhusein, MD, Assistant Professor and Clinical Investigator, Toronto Centre for Liver Disease, University of Toronto, highlighted the efficacy after 3 months of treatment of Seladelpar in patients in Phase 2 and Phase 3 studies that had prior experience with OCA, fibrates, or both.